S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:GOVX

GeoVax Labs (GOVX) Stock Price, News & Analysis

$2.00
+0.15 (+8.11%)
(As of 03/28/2024 ET)
Today's Range
$1.94
$2.00
50-Day Range
$1.84
$4.57
52-Week Range
$1.82
$11.82
Volume
17,296 shs
Average Volume
40,047 shs
Market Capitalization
$4.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$120.00

GeoVax Labs MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
5,900.0% Upside
$120.00 Price Target
Short Interest
Healthy
0.78% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.72mentions of GeoVax Labs in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$1,118 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($6.64) to ($8.37) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.12 out of 5 stars

GOVX stock logo

About GeoVax Labs Stock (NASDAQ:GOVX)

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

GOVX Stock Price History

GOVX Stock News Headlines

GeoVax Labs (NASDAQ:GOVX) Stock Price Down 3.6%
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
GeoVax Labs Inc (GOVX)
GeoVax to Present at the 36th Annual Roth Conference
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Earnings Outlook For Geovax Labs
GeoVax Labs, Inc. (GOVX)
GeoVax to Present at the 2024 BIO CEO & Investor Conference
GeoVax to Participate in Upcoming December Investor Events
See More Headlines
Receive GOVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GeoVax Labs and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/23/2023
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GOVX
Employees
17
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$120.00
High Stock Price Target
$120.00
Low Stock Price Target
$120.00
Potential Upside/Downside
+5,900.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-25,970,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$80,000.00
Book Value
$3.24 per share

Miscellaneous

Free Float
2,085,000
Market Cap
$4.34 million
Optionable
Not Optionable
Beta
2.91
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. David Alan Dodd (Age 74)
    Chairman, President & CEO
    Comp: $384.2k
  • Dr. Mark J. Newman Ph.D. (Age 69)
    Chief Scientific Officer
    Comp: $291.5k
  • Dr. Kelly T. McKee Jr. (Age 73)
    M.D., M.P.H., Chief Medical Officer
    Comp: $361.03k
  • Dr. Harriet Latham Robinson Ph.D. (Age 86)
    Founder, Chief Scientific Officer Emeritus & Member of Scientific Advisory Board
  • Jeffrey Welch
    Head of Process Development & Manufacturing Operations
  • Dr. John W. Sharkey Ph.D. (Age 68)
    Vice President of Business Development

GOVX Stock Analysis - Frequently Asked Questions

Should I buy or sell GeoVax Labs stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GeoVax Labs in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GOVX shares.
View GOVX analyst ratings
or view top-rated stocks.

What is GeoVax Labs' stock price target for 2024?

1 Wall Street research analysts have issued twelve-month price objectives for GeoVax Labs' shares. Their GOVX share price targets range from $120.00 to $120.00. On average, they expect the company's stock price to reach $120.00 in the next year. This suggests a possible upside of 5,900.0% from the stock's current price.
View analysts price targets for GOVX
or view top-rated stocks among Wall Street analysts.

How have GOVX shares performed in 2024?

GeoVax Labs' stock was trading at $5.4150 at the start of the year. Since then, GOVX stock has decreased by 63.1% and is now trading at $2.00.
View the best growth stocks for 2024 here
.

Are investors shorting GeoVax Labs?

GeoVax Labs saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 16,600 shares, a decline of 50.6% from the February 29th total of 33,600 shares. Based on an average daily volume of 39,000 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.8% of the shares of the company are short sold.
View GeoVax Labs' Short Interest
.

When is GeoVax Labs' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our GOVX earnings forecast
.

How were GeoVax Labs' earnings last quarter?

GeoVax Labs, Inc. (NASDAQ:GOVX) announced its earnings results on Thursday, March, 23rd. The company reported ($3.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.55) by $0.45. During the same quarter in the prior year, the company earned ($33.60) EPS.

When did GeoVax Labs' stock split?

GeoVax Labs's stock reverse split on Wednesday, January 31st 2024. The 1-15 reverse split was announced on Wednesday, January 31st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, January 31st 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Who are GeoVax Labs' major shareholders?

GeoVax Labs' stock is owned by many different institutional and retail investors. Top institutional investors include Armistice Capital LLC (91.38%). Insiders that own company stock include David A Dodd, John W Sharkey, Kelly T Jr Mckee, Mark Reynolds and Randal D Chase.
View institutional ownership trends
.

How do I buy shares of GeoVax Labs?

Shares of GOVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GOVX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners